Celon Pharma SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLCLNPH00015
PLN
19.98
-0.02 (-0.1%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Celon Pharma SA stock-summary
stock-summary
Celon Pharma SA
Pharmaceuticals & Biotechnology
Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
Company Coordinates stock-summary
Company Details
Ul. Ogrodowa 2A, Kielpin , None : 05-092
stock-summary
Tel: 48 22 751593348 519 066531
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Robert Rzeminski
Chairman of the Supervisory Board
Mr. Krzysztof Kaczmarczyk
Independent Member of the Supervisory Board
Dr. Michal Kowalczewski
Independent Member of the Supervisory Board
Mr. Artur Wieczorek
Member of the Supervisory Board
Ms. Urszula Wieczorek
Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
49 Million
(Quarterly Results - Mar 2025)
Net Profit:
-25 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 1,088 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.03

stock-summary
Return on Equity

1.10%

stock-summary
Price to Book

2.80